Open AccessNintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
Author(s) -
Ogata Hiroaki,
Nakagawa Taisuke,
Sakoda Soichiro,
Ishimatsu Akiko,
Taguchi Kazuhito,
Kadowaki Masako,
Moriwaki Atsushi,
Yoshida Makoto
Publication year - 2021
Publication title -
respirology case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.304
H-Index - 9
ISSN - 2051-3380
DOI - 10.1002/rcr2.744
Subject(s) - medicine , nintedanib , nasal cannula , methylprednisolone , pulmonary fibrosis , oxygen therapy , fibrosis , covid-19 , hypoxemia , anesthesia , cannula , surgery , disease , idiopathic pulmonary fibrosis , infectious disease (medical specialty) , lung
A 78‐year‐old Japanese woman with no smoking history suffered from near‐fatal coronavirus disease 2019 (COVID‐19) requiring four‐week invasive mechanical ventilation, with subsequent radiological features of pulmonary fibrosis. Although methylprednisolone gradually improved her respiratory condition, her oxygenation and exercise tolerance had drastically deteriorated, necessitating high‐flow nasal cannula oxygen therapy. In parallel with tapering systemic steroid, the patient was treated with nintedanib. Three months later, the patient was able to walk with a walking aid using oxygen at 4 L/min. The present case is an indication that nintedanib might provide a novel therapeutic approach for managing post‐COVID‐19 fibrosis, although further studies are warranted.